GLP1R and schizophrenia: The total effect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), <i>p</i> = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), <i>p</i> = 0.28]; respectively}.<h4>Conclusion</h4>Our analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia.